GENE ONLINE|News &
Opinion
Blog

2025-03-02|

Study at University of Pittsburgh Explores Why Some with Down Syndrome Avoid Dementia

by Mark Chiang
Share To

A groundbreaking study conducted by the University of Pittsburgh’s Swanson School of Engineering is shedding light on why some individuals with Down syndrome (DS) maintain cognitive stability despite a high risk of developing Alzheimer’s disease (AD)-related dementia. This research could potentially benefit not only those within the DS community but also enhance broader understanding of Alzheimer’s disease.

Individuals with Down syndrome face a lifetime risk exceeding 90% for developing dementia as they age, primarily due to Alzheimer’s disease. However, there remains a subset of the DS population that does not follow this expected pattern. The University of Pittsburgh’s new study aims to uncover the factors contributing to this unexpected cognitive stability in certain individuals with DS.

The findings from this research may provide critical insights into both the progression and possible prevention strategies for Alzheimer’s disease among the general population as well as those with Down syndrome. By identifying why some individuals with DS do not develop dementia, researchers hope to apply these insights towards broader therapeutic approaches for Alzheimer’s disease.

Date: March 1, 2025

Newsflash | Powered by GeneOnline AI

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Weight loss Drugs May Reduce Alzheimer’s Risk in People With Type 2 Diabetes
2025-04-09
Higher Education Linked to Faster Cognitive Decline After Stroke
2025-03-27
How does education affect Alzheimer’s and dementia risk? It’s about more than degree attainment
2025-03-18
LATEST
Finnish Study Finds Brain Biomarkers for Alzheimer’s Detectable in Middle Age
2025-07-14
Blood Test Developed at Medical University of Vienna Predicts Multiple Sclerosis Risk Years Before Symptoms
2025-07-14
University of Tokyo Researchers Develop In Vivo System to Study Senescent Cells in Aging
2025-07-14
Relmada Therapeutics Ends Development of Depression Drug Esmethadone and Terminates Licensing Agreement
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton in Narcolepsy Treatment
2025-07-14
Takeda Pharmaceuticals Reports Positive Phase 3 Trial Results for Narcolepsy Drug Targeting Daytime Sleepiness and Cataplexy
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton Targeting Orexin Proteins in Narcolepsy Treatment
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top